Form 4: ACHV CCO Jaime Xinos Granted 180,000 Stock Options

Achieve Life Sciences' Chief Commercial Officer, Jaime Xinos, was granted 180,000 stock options with an exercise price of $4.36, vesting over four years.

Summary

• Jaime Xinos, Chief Commercial Officer of ACHIEVE LIFE SCIENCES, INC. (ACHV), was granted 180,000 stock options.
• The transaction date for the option grant was January 28, 2025.
• The exercise price for these stock options is $4.36 per share.
• The options will begin vesting on January 28, 2026, with 1/4 of the total award vesting on this first anniversary.
• Following the initial vesting, the remaining options will vest in substantially equal monthly installments over 36 months.
• The options have an expiration date of January 28, 2036.
• Following this transaction, Jaime Xinos beneficially owns 180,000 stock options directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued commitment from a key executive and aligns their financial interests with the company's long-term success through equity incentives.

Positives

• The grant of 180,000 stock options aligns the Chief Commercial Officer's incentives with shareholder interests, encouraging long-term commitment and performance.
• The vesting schedule, tied to continued service, promotes retention of key management personnel.

Risks

• The options are subject to forfeiture if the Reporting Person's provision of service to the Issuer ceases before the vesting dates.

Future Outlook

The vesting schedule for the stock options indicates an expectation of continued service from the Chief Commercial Officer for at least the next four years, aligning with long-term strategic goals.

Industry Context

Stock option grants are a common form of equity compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize key executives. StockSavvy.ai notes this grant is consistent with typical executive compensation structures aimed at aligning management interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a standard practice for executive compensation across the biotech and life sciences sectors, comparable to similar grants at companies like Biogen or Amgen, which often use equity to incentivize long-term value creation.
• The exercise price of $4.36 reflects the market value at the time of grant, a common approach to ensure options provide value only if the stock price appreciates.

Stakeholder Impact

• Shareholders: The grant of stock options to a key executive can align management's interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: This grant may signal stability in the executive team, potentially boosting morale and confidence among other employees.

Next Steps

• The stock options will vest according to the specified schedule, contingent on the Chief Commercial Officer's continued service to the company.

Key Dates

Keywords

ACHV, Achieve Life Sciences, stock options, insider transaction, Form 4, equity compensation, Jaime Xinos, Chief Commercial Officer